CDK14 and Parkinson disease: Since decreasing CDK14 leads to a mild reduction in endogenous α-Syn levels [22], we hypothesize that genetic and pharmacological inhibition of CDK14 reduces α-Syn pathology and PD-like phenotypes in mice and human cells.